CLRB Latest Press Releases

-- November 10, 2026 --

Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:15 AM

-- November 4, 2026 --

Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenstrm Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition Globe Newswire 9:00 AM

-- November 2, 2026 --

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 Globe Newswire 8:00 AM

-- October 27, 2026 --

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 Globe Newswire 7:15 AM

-- October 15, 2026 --

Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenstrm Macroglobulinemia Globe Newswire 7:00 AM

-- September 29, 2026 --

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenstrm Macroglobulinemia Globe Newswire 7:30 AM

-- August 13, 2026 --

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:15 AM

-- July 30, 2026 --

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 Globe Newswire 8:05 AM

-- July 15, 2026 --

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes